Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tosedostat | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 9706
Sealed predictions
- LAP3 in dopamine neurons, braak+0.82 (p 0.007) → -0.11 (p 0.787)receipt 9713
Swarm cases
receipt 9713: LAP3 in dopamine neurons, braak
- power
- full sample +0.12 (p 0.640, n 18), 95% CI -0.37 to +0.55. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.14 (p 0.579, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.15 (p 0.555, n 18). could be the mix.
- skeptic
- leave-one-out range +0.00 to +0.29, sign flips 1; without severely affected donors +0.12 (p 0.640, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LAP3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts